Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

New AI system automates classification of skin lesions

5

Oct 2026

New AI system automates classification of skin lesions

Skin cancer is a global health challenge, with nearly 1.5 million new cases diagnosed in 2024 according to World Health Organization (WHO) data. In response, the University of Alicante (UA) and the Sant Joan d'Alacant University Hospital have collaborated to launch MEL-IA (MobilE skin Lesion dIAgnosis), an artificial intelligence system designed to automate the classification of skin lesions.

New study investigates PFAS exposure and future inflammatory bowel disease

5

Oct 2026

New study investigates PFAS exposure and future inflammatory bowel disease

Exposure to per- and polyfluoroalkyl substances (PFAS), often called "forever chemicals," may play a role in the development of inflammatory bowel disease (IBD) years before symptoms appear, according to a new five-year study supported by a $3.3 million National Institutes of Health (NIH) R01 grant to researchers at the Icahn School of Medicine at Mount Sinai.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.